Center for Drug Evaluation and Research (CDER)
CDER is the division of FDA responsible for regulating pharmaceutical drugs (except biologic drugs), including their safety and efficacy.
More information about Center for Drug Evaluation and Research (CDER)
Devices,medical devices,Center for Devices and Radiological Health,decision,study,links,Center,assessment,safe radiation-emitting products,care,efforts,public health,premarket approvals,quality medical,Substantial Equivalence,Humanitarian Device,Humanitarian Use Device,radiation-emitting devices.
Diagnostic devices,investigational device,regulatory decision,health care providers,practices,human exposure,initiative,office,Office of Communication,draft guidance,clinical utility,Electronic products,Food and Drug Administration,Benefit-Risk Determinations,Device Innovation Consortium,Medical Device Innovation Consortium,medical device ecosystem,breakthrough devices,Device Identification.
Device investigational,device labelinghttps://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-preference-information-voluntary-submission-review-premarket-approval-applications,Device ResearchPresentationExternal,device user fee amendments,heart failure devices,humanitarian device exemption applications,medical device companies,medical device development communities,medical device premarket approvals.
Medical device product availability,medical device regulatory benefit-risk determinations,medical device software,medical device user fee,mixed-methods approachExpert Rev Med Devices,GuidancePresentationExternal Link Disclaimer,DevicesPresentationExternal Link Disclaimer,OverviewPresentationExternal Link Disclaimer,ProgramPresentationExternal Link,ActivitiesPresentationExternal Link,ControlsPresentationExternal Link Disclaimer,DecisionsPresentationExternal Link Disclaimer,InspectionPresentationExternal Link Disclaimer,InvestigationsPresentationExternal Link,Document Mail Center,Center for Devices and Radiological Health, Document Mail Center,Center for Biologics Evaluation and Research, Food and Drug Administration,Center for Devices and Radiological Health, Division of Mammography Quality and Radiation Programs,Center for Devices and Radiological Health, Division of Small Manufacturers,Center for Drug Evaluation and Research, Food and Drug Administration,medical product centers,benefit-risk decision,reimbursement decision,coverage decisions,inclusion in decision summaries,Health Care Personnel,CIBA Vision Care,care partner,clinical care paradigms,clinical studies,definition study,feasibility studies,regulatory assessment,benefit-risk assessments,Administrative practice,evidence-based practadrugs,Center for Drug Evaluation and Research,agency,request,guidance,drug applications,generic drugs,documents,clinical trials,U.S. Food and Drug Administration,investigational drugs,counter drugs,effective drugs,human drugs,prescription drugs,safety of drugs,health,health care providers,public health,response,studies,trials,approval,prevention,effectiveness,regulatory actions,form,methods,review,requirement,dandruff shampoos,fluoride toothpaste,biological products,Food and Drug Administration,Center for Drug Evaluation,Center for Drug Evaluation and Research, Food and Drug Administration,drug regulatory,investigational drug development programs,drug shortages,drug treatments,patterns of drug use,access to drugs,adverse drug events,biotech drug products,compassionate use drugs,complex drug substances,compliance with drug product,Drug Administrationthe,drug delivery product,drug developers,drug development,Drug Division,drug for sale,drug in question,drug products,drug product labeling,drug product options,drug product shortages,drug registration status,drug regulation,drug safety,Drug shortage situations,Drug sponsors,drug supply chains,FDA-approved drug applications,generic drug applications,imaging drug,investigational drug products,Investigational New Drug,issues in drug therapy,JAMA Health Forum,public health emergencies,U.S. Public Health Service Commissioned Corps,adverse health outcomes,health benefits,health care practitioners,health of consumers,health of people,health responders,Central Document Room,OGD Document Room,Document Details,Document Statistics,document tracking,(COVID-19) response,component of emergency response,COVID-19 emergency response,COVID-19 outbreak response,emergency response resources,postmarket studies,bioequivalence studies,epidemiologic studies,innovations in study designs,confirmatory trial,findings from Trial,federal agencies,federal government agencies,accelerated approval,decisions on approval will,Centers for Disease Control and Prevention,Disease Control and Prevention,formal requests,access requests,evidence of effectiveness,evaluation of effectiveness,Guidance for industry,guidance for industry entitled,action,action against products,original form,Disclosure forms,active surveillance methods,computational methods,priority review,19491552 Review,recordkeeping requirements,formulary requirementsices,evaluation of radiation exposure,exposure guides,Kidney Health Initiative,patient preference initiative,Office of Compliance,collaborative efforts,joint efforts.